Moderna’s vaccine for the treatment of COVID-19 has received full approval from the US Food and Drug Administration for people 18 years of age or older, an important step that promotes the use of the vaccine as a major weapon in the war once morest Corona.
The vaccine, called Spikevax, was used in US adults under an emergency use authorization from the Food and Drug Administration, but the full clearance allows Moderna to market the vaccine to adults with full FDA approval.
Moderna’s stock jumped 2.8% to $163.93. The company had applied for approval last June.
It is worth noting that Pfizer has the only other fully authorized vaccine in the United States, which was approved by the Food and Drug Administration in August.
